Compare BFRG & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | ADXN |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 8.6M |
| IPO Year | 2022 | 2019 |
| Metric | BFRG | ADXN |
|---|---|---|
| Price | $0.58 | $3.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 116.3K | ★ 125.7K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,670.00 | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.49 | N/A |
| 52 Week Low | $0.43 | $3.73 |
| 52 Week High | $2.04 | $12.05 |
| Indicator | BFRG | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 33.83 |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.69 | $7.48 |
| Average True Range (ATR) | 0.04 | 0.56 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 44.62 | 12.53 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.